Completed PHASE2 INTERVENTIONAL NCT00003754

Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers

A Phase II Study of Thalidomide and Cyclophosphamide in Patients With Recurrent or Refractory Malignancies

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Unspecified Childhood Solid Tumor, Protocol Specific

Interventions cyclophosphamide thalidomide

Updated 5 times since 2017 Last updated: Jun 24, 2013 Started: Sep 30, 1998 Primary completion: Jul 31, 2001 Completion: Jul 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Unspecified Childhood Solid Tumor, Protocol Specific, this trial is completed. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 5 data snapshots since 1998. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States